"The important thing is that patients get treated. And despite the fact that our selling cycle is a little longer, we're not slowing down. We're continuing to build the foundation for this product. And I do believe that you can expect to see the B-cell market grow significantly, not only because of the work that we're doing, but because this is really bringing a high-efficacy therapy to patients upfront, and that could radically change the way that physicians think about and treat multiple sclerosis patients. So we've said that we are ready. We just need this market to bounce back."